Albert David FY26 Net Loss ₹149.47 Lakh; Results Published in Newspapers per SEBI LODR
Albert David Limited reported a net loss of ₹149.47 lakh for FY26, reversing from a net profit of ₹1720.08 lakh in FY25, with revenue from operations declining to ₹33359.81 lakh. The Board recommended a final dividend of ₹5.00 per share and appointed Mr. Amit Mahla as CEO. In compliance with Regulation 47 of SEBI LODR, the audited financial results extract was published in Financial Express and Aajkaal on May 13, 2026.
*this image is generated using AI for illustrative purposes only.
Albert David Limited reported audited financial results for the quarter and financial year ended March 31, 2026, posting a net loss of ₹149.47 lakh for the full year. This represents a significant reversal from the net profit of ₹1720.08 lakh recorded in the previous fiscal year. Revenue from operations for FY26 stood at ₹33359.81 lakh, declining from ₹34576.80 lakh in FY25. Total income for FY26 was ₹34105.14 lakh against ₹37534.87 lakh in FY25, while total expenses were ₹34052.65 lakh compared to ₹35012.10 lakh previously. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 12, 2026. In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, an extract of the audited financial results was subsequently published in Financial Express (All India) and Aajkaal (Bengali Newspaper) dated May 13, 2026, as confirmed by Company Secretary & Compliance Officer Lalit Lohia.
Quarterly Performance
For the quarter ended March 31, 2026, Albert David reported a net loss of ₹2143.44 lakh, widening from a net loss of ₹1032.79 lakh in the corresponding quarter of the prior year. Revenue from operations for the quarter was ₹8586.34 lakh, compared to ₹7489.33 lakh in the same period last year. Total income for the quarter stood at ₹6102.50 lakh, while total expenses amounted to ₹8625.88 lakh. The loss before tax for the quarter was ₹2523.38 lakh, against a loss before tax of ₹1180.87 lakh in the year-ago quarter. The figures for the quarter ended March 31, 2026 represent the balancing figure between the audited full-year figures and the published unaudited year-to-date figures up to the third quarter.
Financial Performance Summary
The following table presents the key financial metrics for the full year and the latest quarter:
| Metric: | Q4 FY26 (₹ in Lacs) | Q4 FY25 (₹ in Lacs) | FY26 (₹ in Lacs) | FY25 (₹ in Lacs) |
|---|---|---|---|---|
| Revenue from Operations: | 8586.34 | 7489.33 | 33359.81 | 34576.80 |
| Other Income: | -2483.84 | -511.44 | 745.33 | 2958.07 |
| Total Income: | 6102.50 | 6977.89 | 34105.14 | 37534.87 |
| Total Expenses: | 8625.88 | 8158.76 | 34052.65 | 35012.10 |
| Profit/(Loss) Before Tax: | -2523.38 | -1180.87 | 52.49 | 2522.77 |
| Net Profit/(Loss): | -2143.44 | -1032.79 | -149.47 | 1720.08 |
| Total Comprehensive Income: | -1906.54 | -1150.56 | 190.68 | 1606.58 |
| Basic EPS (₹): | -37.56 | -18.10 | -2.62 | 30.14 |
| Diluted EPS (₹): | -37.56 | -18.10 | -2.62 | 30.14 |
Balance Sheet Highlights
The statement of assets and liabilities as of March 31, 2026, showed total assets at ₹51913.28 lakh, a slight increase from ₹51141.56 lakh in the previous year. Total equity stood at ₹39153.63 lakh as against ₹39248.34 lakh in the prior year, comprising equity share capital of ₹570.72 lakh and other equity of ₹38582.91 lakh. Total current assets were ₹37440.29 lakh, while total current liabilities stood at ₹11543.02 lakh. Current borrowings rose to ₹2847.76 lakh from ₹1004.92 lakh in the previous year.
| Parameter: | 31.03.2026 (₹ in Lacs) | 31.03.2025 (₹ in Lacs) |
|---|---|---|
| Total Assets: | 51913.28 | 51141.56 |
| Total Equity: | 39153.63 | 39248.34 |
| Total Non-Current Assets: | 14472.99 | 15736.77 |
| Total Current Assets: | 37440.29 | 35404.79 |
| Total Non-Current Liabilities: | 1216.63 | 1475.22 |
| Total Current Liabilities: | 11543.02 | 10418.00 |
| Current Borrowings: | 2847.76 | 1004.92 |
Cash Flow Overview
The company's cash flow statement for the year ended March 31, 2026, showed net cash used in operating activities of ₹765.85 lakh, compared to ₹2843.58 lakh in the prior year. Net cash used in investing activities was ₹439.98 lakh, while net cash from financing activities stood at ₹1192.16 lakh. Closing cash and cash equivalents were ₹29.91 lakh, down from ₹41.73 lakh at the start of the year. The cash flow statement was prepared under the indirect method as per Ind AS-7.
| Cash Flow Item: | FY26 (₹ in Lacs) | FY25 (₹ in Lacs) |
|---|---|---|
| Net Cash from Operating Activities: | -765.85 | -2843.58 |
| Net Cash from Investing Activities: | -439.98 | 2330.13 |
| Net Cash from Financing Activities: | 1192.16 | 11.03 |
| Closing Cash and Cash Equivalents: | 29.91 | 41.73 |
Audit Opinion and Dividend
M/s. L. B. Jha & Co., Chartered Accountants (Firm Registration No. 301088E/E300295), Statutory Auditors of the company, issued the Audit Report with an unmodified opinion on the financial results for the quarter and year ended March 31, 2026. The audit was signed by Partner Ranjan Singh (Membership No. 305423) at Kolkata on May 12, 2026. The Board of Directors recommended a final dividend of ₹5.00 per share of face value ₹10 each for the financial year ended March 31, 2026, subject to approval of shareholders at the 87th Annual General Meeting. The company has fixed July 30, 2026, as the record date for determining eligibility for the dividend and voting at the AGM. The register of members and share transfer books will remain closed from July 31, 2026, to August 6, 2026.
Board Decisions and Appointments
The Board appointed Mr. Amit Mahla as the Chief Executive Officer (CEO) of the company with effect from May 12, 2026, following the resignation of Mr. Umesh Manohar Kunte from the post of Managing Director & CEO. Mr. Mahla, aged approximately 52 years, brings over 28 years of experience in the pharmaceutical industry and has previously been associated with organisations including Cipla, Emcure, Glenmark, Alembic, Sun Pharma, and JB Pharma. He holds a degree in Science, a postgraduate degree in English Literature, and an Executive MBA from SIES, Mumbai. The board also re-appointed M/s. PricewaterhouseCoopers Services LLP as Internal Auditors and M/s. S. Gupta & Co. as Cost Auditors for the financial year 2026-27. The 87th AGM is scheduled to be held on August 6, 2026, via video conferencing.
Related Party Transactions
As part of the integrated filing for the half year ended March 31, 2026, the company disclosed related party transactions totalling ₹175.19 lakh during the reporting period. Key transactions included remuneration of ₹110.67 lakh to Mr. Arun Kumar Kothari (Chairman & Executive Director), legal charges of ₹32.16 lakh to Khaitan & Co. LLP, purchases of goods or services worth ₹20.89 lakh from Gillander Arbuthnot and Company Limited, and ₹9.37 lakh from Strategic Marketing Solutions & Research Centre Private Limited. All transactions were ratified by the Audit Committee. The company confirmed that no deviation or variation in the utilisation of funds raised through public, rights, or preferential issues was applicable, and there were no outstanding defaults on loans or debt securities.
Historical Stock Returns for Albert David
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.80% | -12.72% | -2.13% | -14.69% | -20.37% | +59.94% |
How might newly appointed CEO Amit Mahla's experience at major pharma firms like Cipla and Sun Pharma translate into a concrete turnaround strategy for Albert David's declining revenue and profitability?
Given the sharp rise in current borrowings from ₹1004.92 lakh to ₹2847.76 lakh and negative operating cash flow, how sustainable is Albert David's decision to recommend a ₹5 dividend per share?
What specific product segments or market dynamics are driving Albert David's revenue decline, and could further pricing pressure or competition erode the company's market position in FY27?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
